Studies

35 studies · Download as JSON

• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic ReviewSystematic review · 2026 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• FDA prescribing information: Exenatide (EXENATIDE) - label effective 2026-05-27Regulatory document · 2026 · Not rated · Population unclear · Mixed · Not peer reviewed · Unreviewed automatic assessment
• Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trialsMeta-analysis · 2026 · Study tier 2 · Partial match · Null
• FDA prescribing information: Byetta (EXENATIDE) - label effective 2025-09-02Regulatory document · 2025 · Not rated · Population unclear · Mixed · Not peer reviewed · Unreviewed automatic assessment
• Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trialRandomized trial · 2025 · Study tier 3 · Partial match · Unclear · Unreviewed automatic assessment
• Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialRandomized trial · 2025 · Study tier 1 · Partial match · Null
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsMeta-analysis · 2025 · Study tier 1 · Different population · Benefit
• Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trialRandomized trial · 2024 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysisMeta-analysis · 2024 · Study tier 2 · Population unclear · Unclear · Unreviewed automatic assessment
• Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trialsRandomized trial · 2022 · Study tier 1 · Different population · Unclear · Unreviewed automatic assessment
• Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndromeRandomized trial · 2021 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trialRandomized trial · 2021 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
• Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trialRandomized trial · 2020 · Study tier 3 · Population unclear · Unclear · Industry funded · Unreviewed automatic assessment
• Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trialRandomized trial · 2020 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2017 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trialRandomized trial · 2017 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysisMeta-analysis · 2016 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide studyRandomized trial · 2015 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markersRandomized trial · 2014 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetesRandomized trial · 2014 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver diseaseRandomized trial · 2013 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trialRandomized trial · 2013 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetesRandomized trial · 2012 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trialRandomized trial · 2012 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Exenatide exerts a potent antiinflammatory effectRandomized trial · 2012 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patientsRandomized trial · 2011 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitusRandomized trial · 2011 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body compositionRandomized trial · 2010 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Exenatide versus glibenclamide in patients with diabetesRandomized trial · 2010 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment